Factors Influencing Treatment Response in Patients with Malignant Otitis Externa


Pithiwat Wongwan, M.D.1, Kanthong Thongyai, M.D.2,*, Suvajana Atipas, M.D.2, Sarun Prakairungthong, M.D.2, Siriporn Limviriyakul, M.D.2, Kanokrat Suvarnsit, M.D.2, Herman Jenkins, M.D.3

1Department of Otorhinolaryngology, Chonburi Hospital, Chonburi, Thailand, 2Department of Otorhinolaryngology, Faculty of Medicine Siriraj

Hospital, Mahidol University, Bangkok, Thailand, 3Department of Otolaryngology-Head and Neck Surgery, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA.



*Corresponding author: Kanthong Thongyai E-mail: kanthong@gmail.com

Received 6 December 2024 Revised 25 January 2025 Accepted 5 February 2025 ORCID ID:http://orcid.org/0000-0001-8987-6006 https://doi.org/10.33192/smj.v77i4.272587


All material is licensed under terms of the Creative Commons Attribution 4.0 International (CC-BY-NC-ND 4.0) license unless otherwise stated.


ABSTRACT

Objective: To identify factors affecting treatment outcomes in patients with malignant otitis externa (MOE). Materials and Methods: A retrospective review of MOE treatment was conducted in patients aged > 18 years admitted to Siriraj Hospital from January 2007 to December 2022. Predictors of treatment response chosen included duration of hospitalization, duration of antimicrobial treatment, disease-related re-admissions, and mortality.

Results: The study included 49 patients (33 males, 16 females) with a mean age of 65±12 years. Comorbidities were present in 90% of patients, with diabetes mellitus being the most common. Pseudomonas aeruginosa was identified in 37% of cases. Bilateral symptoms/infections were reported in 18%. Facial nerve palsy and non-cranial nerve complications were 51% and 12%, respectively. Computed tomography (CT) imaging revealed bony erosion in 75% of patient. Surgical management was performed in 73% of patients. The median duration of hospital stays and antimicrobial treatment were 34 days and 143 days, respectively. Readmissions due to disease progression occurred in 35%, and the mortality rate was 4%. Bone erosion on CT was associated with an increased likelihood of readmission. Prolonged hospital stays were associated with bilateral symptoms and positive CT findings. Extended antimicrobial treatment was linked to multiple comorbidities, bilateral symptoms, non-cranial nerve complications, positive CT findings, and surgical cases.

Conclusion: Various factors influence treatment outcomes in MOE patients. Early diagnosis, aggressive treatment, and management of prognostic factors are essential for preventing severe complications and improving survival outcomes.

Keywords: Otitis externa; necrotizing otitis externa; osteomyelitis; risk factors; patient outcome assessment; diabetes mellitus; malignant otitis externa (Siriraj Med J 2025; 77: 257-266)


INTRODUCTION

Malignant otitis externa (MOE), also known as necrotizing otitis externa (NOE), was first reported by Toulmouche in 1838 and later described by Chandler in 1968.1,2 It is a rare, non-cancerous but potentially life-threatening infection of the external ear that can progressively spread via various anatomical pathways to adjacent structures, including the mastoid, skull base, and cranial nerves. This extension may result in serious complications, including cranial neuropathies, brain abscesses, meningitis, and dural venous sinus thrombosis.3 MOE primarily affects older adults, particularly males, and is more common among individuals with underlying diabetes mellitus (DM) or other immunocompromised conditions, including malignancies, use of immunosuppressive drugs, and Acquired Immune Deficiency Syndrome (AIDS). Immunosuppressed patients due to HIV or other non-diabetic factors may develop MOE at a younger age compared to those with diabetes.4,5 The most common pathogen is Pseudomonas aeruginosa, but MOE may result from other pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA), Klebsiella, and Proteus mirabilis. Fungal species, including Aspergillus and Candida, are also notable causative

agents.6,7

Common presenting symptoms are persistent otorrhea and otalgia, particularly at night, that do not respond to topical antibiotic treatment. Physical examination

often reveals a painful, erythematous, and edematous ear canal with discharge. The presence of granulation tissue at the bony-cartilaginous junction is suggestive of a Pseudomonas infection.8 In addition to frequent involvement of the facial nerve, other cranial nerves, including the glossopharyngeal, vagus, spinal accessory, hypoglossal, abducens, and trigeminal nerves, may be affected. Laboratory and imaging studies are essential for diagnosis and management. In a recent systematic review identified 27 different diagnostic criteria for MOE.9 Treatment generally requires prolonged systemic antimicrobial therapy, aural cleaning and blood sugar control, with some cases necessitating hyperbaric oxygen therapy. Surgery is generally reserved for severe cases that are unresponsive to medical management.8

Although rare, the incidence of MOE varies across studies, with recent systematic reviews estimating it at between 0.22 and 1.19 cases per 100,000 individuals.10 No official incidence data is available for Thailand. This study aims to identify factors that influence MOE treatment outcomes in patients at Siriraj Hospital, thus providing an initial exploration of this condition in the Thai population.


MATERIALS AND METHODS

A retrospective review was conducted using the database of the Department of Otorhinolaryngology at Siriraj Hospital. The study included all patients over

18 years of age who were admitted for malignant otitis externa between January 1st, 2007, and December 31st, 2022. Diagnoses made by otologists in the department were based on four out of seven items from Levenson’s criteria: refractory otitis externa, severe nocturnal otalgia, purulent otorrhea, granulation tissue in the external auditory canal, positive Pseudomonas culture, presence of an immunocompromised state or diabetes, and a positive technetium bone scan.11

Data collected from medical records included age, sex, comorbidities, physical examination findings, treatment details, biochemical results, culture and biopsy results, imaging studies, and follow-up information. Potential predictors of treatment response were defined as the duration of hospitalization, length of antimicrobial therapy, disease-related hospital readmission, and mortality. Cases with incomplete data or those managed exclusively on an outpatient basis were excluded from the study. Ethical approval for the study was obtained from the institutional Ethics Committee.

Statistical analyses

Descriptive statistics summarized demographic characteristics such as age and sex. Quantitative data are presented as mean ± standard deviation or median (interquartile range), while qualitative data are shown as frequencies or percentages.

To analyze hospital readmission rates, we used the independent t-test for normally distributed quantitative variables and the Mann-Whitney U test for skewed distributions. Pearson’s chi-square or Fisher’s exact test assessed associations between qualitative variables.

The Pearson’s correlation coefficient was used for univariate analysis of hospitalization time and antimicrobial therapy. Variables with p-values less than 0.2 in univariate analysis were selected for multivariate analysis using logistic regression for readmission factors and linear regression for hospital and antimicrobial durations.

Survival data were analyzed using Kaplan-Meier survival curves.

All statistical analyses were performed using PASW Statistics 18 (SPSS Inc., Chicago, IL, USA), with significance set at p < 0.05.

RESULTS

Patient characteristics

A total of 49 patients were included in the study, consisting of 33 men and 16 women, with ages ranging from 42 to 91 years, with a mean of 65±12 years. Of these, 44 patients (90%) had multiple comorbidities. The most common underlying condition was diabetes mellitus

(98%), followed by hypertension (71%) and chronic kidney disease (39%). Two patients were diagnosed with malignancies (breast cancer and lymphoma).

Physical examination and investigations

The median duration of symptoms was approximately 60 days. Symptoms were predominantly observed in the right ear, with 23 patients (43%) presenting symptoms exclusively on the right side, while nine (18%) experiencing symptoms in both ears. On physical examination, purulent otorrhea was observed in 45 patients (92%), and otalgia was noted in 45 patients (92%). Granulation tissue was identified in 38 (78%) cases. Facial nerve paralysis, a common otologic complication, was documented in 25 patients (51%). Additionally, advanced MOE involved other cranial nerves: cranial nerve VI (two patients), X (one patient), IX (one patient), and XII (one patient). Six patients presented with other complications, including infratemporal abscess, sigmoid sinus thrombosis, and parotid abscess.

Inflammatory markers were useful for both diagnosis and follow-up in cases of MOE. The erythrocyte sedimentation rate (ESR) was elevated in 43 patients (88%), with values ranging from 17 to 119 mm/hour. C-reactive protein (CRP) levels were elevated in 27 patients (55%), ranging from 0.6 to 287 mg/L. Computed tomography (CT) scan revealed erosion of the temporal bone and soft tissue in the ear canal in 37 patients (75%). Technetium scans (Tc-99m) were performed on 29 patients, all of which showed positive findings. Additionally, 31 patients had absorption or positive gallium scans (Ga-67).

Pathogenic microorganisms and pathological diagnosis Themostfrequentlyisolatedpathogenwas Pseudomonas aeruginosa, found in 18 patients (37%). Fungal pathogens were isolated in 16 patients, while cultures were negative in 15 cases. Granulation tissue and inflammation were

present in almost all cases (86%; 42 out of 49).

Treatment

Medical therapy was the primary treatment approach, with a median treatment duration of 191 days. All patients received predominantly ceftazidime antibiotic therapy, with 92% requiring intravenous administration. Sixteen patients with fungal infections received antifungal treatment with voriconazole or itraconazole in addition to antibiotics. Surgical intervention was necessary for 36 patients (73%), mostly in the form of various types of mastoidectomy (27 cases). Other procedures included ear canal debridement, and local incision and drainage.

Prognosis and risk factors

Table 1 summarizes the overall response outcomes of the group. The median duration of hospital stay for the 49 patients was 34 days, with a median 143 days duration of antimicrobial treatment. The in-hospital mortality rate included two patients (4%), while rehospitalization was required in 20 patients (41%), including disease progression in 17 patients and Gallium scan preparation in 3 patients.

Disease-related hospital readmission

Twenty patients treated at Siriraj Hospital required readmission and the data for this group are presented in Table 2 and analysis of the different variables in Table 3. Notably, erosion of the temporal bone noted on CT scan (90%; 18 out of 20) was significantly associated with an increased likelihood of readmission (p = 0.03). Other factors, though not statistically significant, included symptoms, duration of more than 60 days, the non-cranial nerve involvement complications, positive technetium and gallium scans, and undergoing surgery.

Length of Hospital Stay (LOS)

The median length of hospitalization was 34 days (range: 18 to 58 days). Infections involving both ears and temporal bone erosion observed on CT scan were statistically significant factors contributing to a longer hospital stay (Table 4).

Duration of antimicrobial treatment

As shown in Table 5, the median duration of antimicrobial therapy was 143 days (range: 78 to 290 days). Patients with comorbidities, bilateral ear infections, non-cranial nerve complications, positive CT scan findings,

and those who underwent surgery tended to have a significantly longer antimicrobial treatment.

In-Hospital mortality

The overall survival rate was 96%. Two patients died at 2 months and 14 months, respectively, due to progressive disease process (Fig 1). The first was a 75-year- old woman with diabetes mellitus, hypertension, and end-stage renal disease, dying from meningitis and sepsis. The second was a 90-year-old man with diabetes mellitus, hypertension, and a history of myocardial infarction, who succumbed to septic shock.


DISCUSSION

MOE is a rare but potentially life-threatening infection of the external ear, with a prevalence ranging between 0.22 and 1.19 cases per 100,000 patients.10 Due to the condition’s rarity, formal studies in Thailand are limited. This 16-year study, involving 49 patients, aimed to identify factors that influence treatment outcomes, providing valuable insights for future research.

Elderly patients (age ≥ 65 years) are consistently identified as being at higher risk for poor prognosis in numerous studies, with advanced age correlating with extended hospitalization and increased mortality rates.3,6 However, in this study, age was not a predictor of poor outcomes. Diabetes mellitus is widely recognized as a significant risk factor for MOE, with reported prevalence between 65% and 85% in recent studies.12,13 Some studies link diabetes mellitus with poor treatment outcomes, whereas others do not.12,14,15 In this study, 98% of patients had diabetes mellitus, however, it did not significantly correlate to worse outcomes. Additionally, neither poorly nor well-controlled diabetes (as indicated by HbA1c and


TABLE 1. Treatment response outcomes.


Treatment response

Total (N=49)

Numbers of cases (percentage) Days: Median (25%, 75%)

Hospital readmission (cases) 20 (41)*


Death (cases) 2 (4)

Hospitalization time (days) 34 (18, 58)


Duration of antimicrobial (days) 143 (78, 290)

*17(35) readmission due to disease progression, 3(6) readmission due to Gallium scan


TABLE 2. Baseline characteristics of patients with readmission outcomes.



Total


N = 49 (%)

Re-admission No

N = 29 (%)


Yes

N = 20 (%)

p-value

Sex





Male

33 (67)

20 (69)

13 (65)

0.77

Female

16 (33)

9 (31)

7 (35)


Age (years)





<65 years

25 (51)

15 (52)

10 (50)

0.91

≥ 65 years

24 (49)

14 (48)

10 (50)


Diabetes Mellitus

48 (98)

28 (97)

20 (100)

1.00

HbA1c





Good control

14 (31)

8 (31)

6 (32)

0.95

Poor control ( ≥7 mg%)

31 (69)

18 (69)

13 (68)


Fasting blood sugar:





Good control

13 (27)

7 (25)

6 (30)

0.75

Poor control (≥130 mg/dl)

35 (73)

21 (75)

14 (70)


Non-diabetic underlying disease

44 (90)

25 (86)

19 (95)

0.64

BMI (kg/m2)

23 ± 4

22 ± 4

23 ± 5

0.33

Affected ears:





Right

21 (43)

13 (45)

8 (40)

0.61

Left

19 (39)

12 (41)

7 (35)


Bilateral

9 (18)

4 (14)

5 (25)


Duration day (days)

60 (14, 60)

30 (7, 60)

60 (30, 105)

0.05

(First day of symptom to the first day of hospital visit)

Duration of ≥ 60 days

25 (51)

12 (41)

13 (65)

0.10

Clinical presentation





Otalgia

45 (92)

27 (93)

18 (90)

1.00

Purulent otorrhea

45 (92)

25 (86)

20 (100)

0.13

Granulation tissue

38 (78)

25 (86)

13 (65)

0.09

Cranial nerve involvement

27 (55)

15 (52)

12 (60)

0.57

Non-cranial nerve involvement complications

6 (12)

2 (7)

4 (20)

0.21

Inflammatory markers





Erythrocyte sedimentation rate (ESR) (mm/hour)

81 (63, 98)

80 (51, 103)

83 (72, 98)

0.61

C-reactive protein (CRP) (mg/l)

23 (8, 47)

30 (6, 47)

22 (9, 57)

0.62

Pathogens

Pseudomonas aeruginosa

18 (37)

10 (34)

8 (40)

0.69

Fungus

16 (33)

11 (38)

5 (25)

0.34

Pathology





Granulation and inflammation

42 (86)

24 (83)

18 (90)

0.68

CT scan: positive result

37 (76)

19 (66)

18 (90)

0.09

Technetium scan: positive

29 (59)

14 (48)

15 (75)

0.06

Gallium scan: positive

31 (63)

16 (55)

15 (75)

0.16

Surgery

36 (73)

19 (66)

17 (85)

0.13


TABLE 3. Re-hospitalization based on different variables.



Crude Odds ratio (95%CI)

P-value

Adjusted Odds ratio (95%CI)

P-value

Duration range ≥ 60 days

2.63 (0.81, 8.55)

0.11



Granulation tissue

0.30 (0.07, 1.20)

0.09

0.26 (0.05, 1.31)

0.10

Non-cranial nerve involvement complications

3.38 (0.55, 20.55)

0.18

4.96 (0.63, 39.36)

0.13

CT scan: positive

4.73 (0.91, 24.65)

0.07

8.62 (1.16, 63.86)

0.03

Technetium scan: positive

3.21 (0.92, 11.18)

0.07



Gallium scan: positive

2.43 (0.69, 8.49)

0.16

2.81 (0.69, 11.40)

0.15

Surgery

2.98 (0.70, 12.67)

0.14



*Logistic regression was used for multivariate analyses for all p-values less than 0.2 in univariate analysis with backward selection variable (p-value for removal equal to 0.17)


TABLE 4. Hospitalization duration in relation to different variables.



Univariable analysis

Coefficient


P-value

Multivariable analysis

Coefficient


P-value

(95%CI)


(95%CI)


Female

-29.41

0.09




(-63.32, 4.49)




Well-controlled HbA1c

-27.74

0.14




(-65.11, 9.63)




Bilateral ears affected

47.34

0.02

59.76

0.00


(7.31, 87.37)


(19.67, 99.86)


Fungal infection

24.69

0.15




(-9.53, 58.92)




CT scan: positive result

39.17

0.03

47.08

0.01


(2.79, 75.55)


(11.13, 83.03)


Technetium scan: positive

36.91

0.02




(5.33, 68.48)




Gallium scan: positive

26.38

0.12




(-6.76, 59.52)




Surgery

30.80

0.09

27.26

0.12


(-5.24, 66.85)


(-7.32, 61.85)


*Linear regression was used for multivariate analyses for all p-values less than 0.2 in univariate analysis with backward selection variable (p-value for removal equal to 0.17)


TABLE 5. Duration of antimicrobials in relation to different variables.


Univariable analysis Multivariable analysis


Coefficient

(95%CI)

P-value

Coefficient

(95%CI)

P-value

Non-diabetic underlying diseases

111.64

0.18

146.01

0.03


(-54.94, 278.22)


(17.01, 275.01)


Otorrhea

126.25

0.17

101.63

0.16


(-57.74, 310.25)


(-43.36, 246.61)


Bilateral ears affected

113.51

0.08

142.32

0.01


(-14.96, 241.98)


(36.56, 248.08)


Non-cranial nerve involvement complications

146.68

0.06

121.06

0.04


(-4.07, 297.42)


(3.01, 239.11)


CT scan: positive result

110.62

0.06

126.97

0.01


(-4.39, 225.63)


(27.21, 226.72)


Technetium scan: positive

134.92





(38.14, 231.69)

0.00



Gallium scan: positive

130.32

0.01




(30.82, 229.83)




Surgery

154.62

0.00

149.03

0.00


(47.43, 261.82)


(52.85, 245.21)


*Linear regression was used for multivariate analyses for all p-values less than 0.2 in univariate analysis with backward selection variable (p-value for removal equal to 0.17)


Fig 1. Kaplan-Meier curve showing association between cumulative survival rate and length of treatment (in months). * Cum Survival = cumulative survival rate, ** LOT mos = length of treatment in the month.

fasting blood sugar levels) were not determined to be a prognostic factor. Patients with multiple comorbidities, such as end-stage renal disease and hypertension, often have compromised immune systems and microvascular complications, potentially leading to poor treatment responses. In this study, multiple comorbidities were significantly associated with longer antimicrobial treatment durations, in aligning with findings from Arsovic et al.16 These findings underscore the importance of controlling underlying comorbid conditions when treating MOE. Common symptoms included otalgia, otorrhea,

and granulation tissue. Bilateral ear involvement was statistically associated with longer antimicrobial treatment and extended hospital stays. Facial nerve involvement was the most frequent cranial nerve complication. The prognostic significance of facial nerve palsy is debated; Stevens et al. reported increased mortality with facial nerve palsy, while other studies found no difference in survival.17-19 In this study, facial nerve palsy occurred in 25 patients (51%) but did not predict poorer prognosis. In contrast, non-cranial nerve complications, such as parotid abscess and transverse sigmoid sinus thrombosis, were associated with prolonged antimicrobial treatment. Pseudomonas aeruginosa is reported as the most common pathogen in MOE, implicated in 50-90% of cases.2 In this study, Pseudomonas aeruginosa was found in 37% of cases, fungal pathogens in 32%, and 31% of cultures were negative. This variation may be attributed to the study’s tertiary care center setting, where cases

are often complicated or partially treated.

Inflammatory markers, such as elevated ESR (88%) and CRP (55%), were frequently observed. Although these markers are useful in diagnosing and monitoring MOE, they were not significant prognostic factors for treatment outcomes in this study, which aligns with other reports.20 Imaging plays a critical role in diagnosis and treatment planning. CT scans are valuable for assessing disease extent and identifying anatomical structures for surgical planning. Increased uptake of Technetium-99m (TC- 99m) scans at the temporal bone area helps diagnosing MOE due to being more sensitive test than CT scan for detecting osteogenic activity especially in early or unclear cases. However, Tc99m uptake persists for an infinite period. Gallium-67 (Ga-67), which binds to white blood cells, can detect infection and inflammation. The Ga-67 scans are beneficial for follow-up, as they normalize after resolution of infection. Therefore, the number of patients who needed TC-99m scans for diagnosis are less than the patients who had Ga-67 scans for follow up if they did not need TC-99m for fulfilling Levenson’s criteria.

However, this retrospective study collects data from the past 15 years, during which Ga-67 was not commonly available. As a result, only 30 patients received a follow-up Ga-67 scan. Among those who underwent follow-up with Ga-67, the readmission rate was 36% (11 patients). Most patients who received a Ga-67 scan were followed up in the outpatient department (OPD) setting, as they were transitioned to oral antibiotics once clinical improvement was observed. Therefore, the primary purpose of Ga-67 scans in our setting is to reassess the active inflammatory phase of the disease and decide whether to discontinue antibiotic treatment. The scheduling of Ga-67 scans at our center requires long appointment durations, which means that some patients treated as outpatients may develop progressive disease and require rehospitalization before receiving the scan. Of the 11 patients, two presented with new lesions in another ear after the resolution of the initial lesion. Two patients did not show clinical improvement and continued to exhibit active uptake after discharge. Two required intravenous antibiotics and readmission following pathogen identification. Additionally, two patients were re-hospitalized due to increased Ga-67 uptake, and three patients had progressive lesions before their Ga-67 scans. However, none of the patients identified by the negative Ga-67 scan required readmission due to disease recurrence.

In this study, bony erosion or soft tissue abnormalities on CT scans were significantly associated with poorer outcomes. including higher rates of hospital readmission, longer antimicrobial treatment durations, and extended hospital stays. This finding is consistent with studies linking temporal bone erosion to prolonged hospitalizations.6,16 However, CT imaging may have limitations in detecting early-stage infections, probably explaining why changes were more frequently observed in advanced cases.21,22

The primary treatment for MOE remains systemic antimicrobial therapy, combined with strict control of underlying conditions. Although the optimal duration of antimicrobial treatment is not definitively established, most studies recommend 4 to 6 weeks. Several factors are considered when deciding to discontinue treatment for malignant otitis externa, including resolution of signs and symptoms, negative cultures, normalized inflammatory markers and radionuclide scanning improvement. Due to the aggressive nature of malignant otitis externa, disease progression can still occur despite treatment, highlighting the importance of close monitoring throughout the management process.

At our center, if clinical improvement is observed,

such as resolving painful swollen ear canal, returning to normal in inflammatory markers (ESR and C-reactive protein), and no uptake in a Ga-67 scan, this serves as evidence of antimicrobial discontinuation. Conversely, the presence of suspected active lesions clinically and confirmed by sustained or progressive uptake of Ga-67 inform the decision to pursue further aggressive treatment for MOE.

Surgical intervention is required in severe cases, particularly those involving complications or failure to respond to antimicrobial treatment, to obtain tissue for culture and debride necrotic tissue.23 At our center, the surgical intervention rate is notably high at 73%, which was significantly associated with longer antimicrobial treatment. The most common procedure performed in our setting is simple mastoidectomy as it offers superior tissue samples for culture and pathological evaluation, that is, more helpful in diagnosis and treatment. Mostly our patients are complex cases that were referred from the other hospitals, for example, partially undergone medical treatment or no previous tissue culture. Consequently, when patients experience persistent pain and unresponsiveness to treatment, a definitive tissue diagnosis is necessary. Additionally, granulation tissue in the middle ear and mastoid cavity were primary operative findings. Some studies suggest that early debridement of granulation and necrotic tissue can reduce pain, shorten antibiotic therapy, and expedite healing.24

Previous studies have reported mortality rates of 17.8% to 21%.25 In this study, the in-hospital mortality rate in this study was 4%, suggesting effective management of MOE patients at our institution. Numerous studies have explored factors influencing MOE treatment outcomes, and the findings from this study provide valuable insights for clinicians, supporting the development of effective treatment strategies that result in favorable outcomes. However, this study has limitations, including its retrospective design, relatively small sample size, and restriction to a single-center experience.


CONCLUSION

Multiple factors influence treatment outcomes in patients with malignant otitis externa. Early diagnosis, aggressive therapy, and management of underlying conditions are essential to prevent severe complications, leading to better outcomes and reducing mortality. This is the first formal study of malignant otitis externa in Thailand. Future multicenter studies with larger sample sizes are recommended to expand the understanding of this disease from various perspectives.

Data Availability Statement

The data that support the findings of this study are available upon request from the corresponding author, [K.T.]. The data are not publicly available due to containing information that could compromise the privacy of research participants.


ACKNOWLEDGEMENTS

We extend our heartfelt gratitude to Asst. Prof. Dr. Orawan Supapueng, statistician, and Ms. Jeerapa Kerdnoppakhun for their invaluable assistance in developing this manuscript. We are also deeply thankful to all the patients involved in this study and the staff of the Department of Otorhinolaryngology, Faculty of Medicine Siriraj Hospital, Mahidol University.


DECLARATION

Grants and Funding Information

The authors received no financial support for the research, authorship, or publication of this article.

Conflict of Interest

The authors declare no potential conflicts of interest regarding the research, authorship, or publication of this article.

Registration Number of Clinical Trial

Not registered in the clinical trial due to retrospective study.

Author Contributions

P.W.; Conceptualization, Methodology, Formal analysis, Data Curation, Writing - Review & Editing, Supervision S.A, S.P., S.L., K.S., H.J.; Resources, Methodology, Data Curation, Writing - Original Draft K.T.; Conceptualization, Data Curation, Writing - Review & Editing.

Use of Artificial Intelligence

None

Ethics Committee Approval

Ethics committee approval was obtained for this study from the Siriraj Institutional Review Board (COA no. Si 253/2023).

REFERENCES

  1. Dabholkar JP, Sheth A. Malignant otitis externa. Indian J Otolaryngol Head Neck Surg. 2001;53(1):55-6.

  2. Treviño González JL, Reyes Suárez LL, Hernández de León JE. Malignant otitis externa: An updated review. Am J Otolaryngol. 2021;42(2):102894.

  3. Sylvester MJ, Sanghvi S, Patel VM, Eloy JA, Ying YM. Malignant otitis externa hospitalizations: Analysis of patient characteristics. Laryngoscope. 2017;127(10):2328-36.

  4. Slattery WH, 3rd, Brackmann DE. Skull base osteomyelitis. Malignant external otitis. Otolaryngol Clin North Am. 1996; 29(5):795-806.

  5. Rubin J, Yu VL. Malignant external otitis: insights into pathogenesis, clinical manifestations, diagnosis, and therapy. Am J Med. 1988;85(3):391-8.

  6. Stern Shavit S, Soudry E, Hamzany Y, Nageris B. Malignant external otitis: Factors predicting patient outcomes. Am J Otolaryngol. 2016;37(5):425-30.

  7. Hamzany Y, Soudry E, Preis M, Hadar T, Hilly O, Bishara J, et al. Fungal malignant external otitis. J Infect. 2011;62(3): 226-31.

  8. Al Aaraj MS, Kelley C. Necrotizing (Malignant) Otitis Externa. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Cecylia Kelley declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright© 2024, StatPearls Publishing LLC.; 2024.

  9. Mahdyoun P, Pulcini C, Gahide I, Raffaelli C, Savoldelli C, Castillo L, et al. Necrotizing otitis externa: a systematic review. Otol Neurotol. 2013;34(4):620-9.

  10. Takata J, Hopkins M, Alexander V, Bannister O, Dalton L, Harrison L, et al. Systematic review of the diagnosis and management of necrotising otitis externa: Highlighting the need for high-quality research. Clin Otolaryngol. 2023;48(3): 381-94.

  11. Levenson MJ, Parisier SC, Dolitsky J, Bindra G. Ciprofloxacin: drug of choice in the treatment of malignant external otitis (MEO). Laryngoscope. 1991;101(8):821-4.

  12. Franco-Vidal V, Blanchet H, Bebear C, Dutronc H, Darrouzet

    V. Necrotizing external otitis: a report of 46 cases. Otol Neurotol. 2007;28(6):771-3.

  13. Glikson E, Sagiv D, Wolf M, Shapira Y. Necrotizing otitis externa: diagnosis, treatment, and outcome in a case series. Diagn Microbiol Infect Dis. 2017;87(1):74-8.

  14. Joshua BZ, Sulkes J, Raveh E, Bishara J, Nageris BI. Predicting

    outcome of malignant external otitis. Otol Neurotol. 2008;29(3): 339-43.

  15. Chen JC, Yeh CF, Shiao AS, Tu TY. Temporal bone osteomyelitis: the relationship with malignant otitis externa, the diagnostic dilemma, and changing trends. ScientificWorldJournal. 2014; 2014:591714.

  16. Arsovic N, Radivojevic N, Jesic S, Babac S, Cvorovic L, Dudvarski

    Z. Malignant Otitis Externa: Causes for Various Treatment Responses. J Int Adv Otol. 2020;16(1):98-103.

  17. Stevens SM, Lambert PR, Baker AB, Meyer TA. Malignant Otitis Externa: A Novel Stratification Protocol for Predicting Treatment Outcomes. Otol Neurotol. 2015;36(9):1492-8.

  18. Soudry E, Joshua BZ, Sulkes J, Nageris BI. Characteristics and Prognosis of Malignant External Otitis With Facial Paralysis. Arch Otolaryngol Head Neck Surg. 2007;133(10):1002-4.

  19. Hatch JL, Bauschard MJ, Nguyen SA, Lambert PR, Meyer TA, McRackan TR. Malignant Otitis Externa Outcomes: A Study of the University HealthSystem Consortium Database. Ann Otol Rhinol Laryngol. 2018;127(8):514-20.

  20. Yigider AP, Ovunc O, Arslan E, Sunter AV, Cermik TF, Yigit O. Malignant Otitis Externa: How to Monitor the Disease in Outcome Estimation? Medeni Med J. 2021;36(1):23-9.

  21. Ahmed AA, Rashid S, Gupta VK, Molony NC, Gupta KK. The diagnostic conundrum in necrotizing otitis externa. World J Otorhinolaryngol Head Neck Surg. 2024;10(1):59-65.

  22. Kim DH, Kim SW, Hwang SH. Predictive value of radiologic studies for malignant otitis externa: a systematic review and meta-analysis. Braz J Otorhinolaryngol. 2023;89(1):66-72.

  23. Singh J, Bhardwaj B. The Role of Surgical Debridement in Cases of Refractory Malignant Otitis Externa. Indian J Otolaryngol Head Neck Surg. 2018;70(4):549-54.

  24. Raines JM, Schindler RA. The surgical management of recalcitrant malignant external otitis. Laryngoscope. 1980;90(3):369-78.

  25. Chawdhary G, Pankhania M, Douglas S, Bottrill I. Current management of necrotising otitis externa in the UK: survey of 221 UK otolaryngologists. Acta Otolaryngol. 2017;137(8):

818-22.